Xtant Medical Holdings, Inc. - Form 8-K Summary
Business Context and Reporting Period
Date of Report: July 7, 2025
Company: Xtant Medical Holdings, Inc. (XTNT)
Event: Entry into Material Definitive Agreements to divest specific business units.
On July 7, 2025, the Company entered into agreements to sell its Coflex/CoFix business in the United States and its international hardware business (Paradigm Spine GmbH) to Companion Spine, LLC. The Company also secured consent from its lenders, MidCap Financial Trust and MidCap Funding IV Trust, to proceed with these transactions.
Key Financial Metrics and Transaction Terms
This filing details a divestiture transaction rather than periodic financial performance. Key financial terms include:
- Coflex/CoFix Business Sale Price: $17.5 million total, subject to inventory adjustments.
- Paradigm (International Hardware) Sale Price: $1.7 million total, subject to cash, indebtedness, and working capital adjustments.
- Payment Structure (Coflex/CoFix):
- $2.5 million non-refundable cash deposit paid upon execution.
- Up to two additional $2.5 million deposits possible if financing is delayed.
- Remaining balance at closing: Up to $6.8 million cash and an $8.2 million unsecured promissory note (maturing December 31, 2025).
- Debt Prepayment: Proceeds from the transactions will be used to prepay $9.6 million on the Company's Term Loan with MidCap.
- Indemnification: Subject to a $250,000 deductible and a $2.0 million cap.
Material Changes and Conditions
The filing represents a material change in the Company's asset base and business scope. Key conditions include:
- Financing Contingency: Completion of both transactions is contingent upon the Buyer (Companion Spine) obtaining sufficient financing.
- Interdependency: The closing of the Coflex/CoFix Transaction and the Paradigm Transaction are contingent on each other; both must close simultaneously.
- Timeline: Closing is expected in the third quarter of 2025. A termination date of September 15, 2025, is set, subject to extension if additional deposits are paid.
- Lender Consent: The Company obtained limited consent from MidCap to enter the agreements and prepay $9.6 million of debt.
Outlook, Risks, and Management Commentary
Management has issued a press release regarding the agreements but provided no specific financial guidance for the remainder of the year beyond the transaction details. The filing highlights significant risks:
- Transaction Failure: No assurance that the transactions will close; failure to close could adversely affect the Coflex/CoFix and international hardware businesses.
- Operational Disruption: Risks include diversion of management attention, loss of key employees, and disruption to supplier/customer relationships.
- Payment Risk: Risk that the Buyer may fail to pay the $8.2 million promissory note upon maturity.
- Cost Overruns: Potential for transaction costs to exceed initial estimates, reducing net proceeds.
Investor Verification Checklist
- Verify the Buyer's (Companion Spine) ability to secure the necessary financing to close the deal by September 15, 2025.
- Monitor the status of the $8.2 million promissory note and the Buyer's creditworthiness.
- Confirm the final purchase price adjustments related to inventory, working capital, and indebtedness at closing.
- Assess the impact of the divestiture on the Company's remaining revenue streams and liquidity position post-closing.
- Review the full text of the Asset Purchase Agreement (Exhibit 2.1) and Equity Purchase Agreement (Exhibit 2.2) for specific termination rights and covenants.